TABLE 1.
Studied group | CVID cohort number | Publication year | Diagnosed lymphoma (%) | Comments |
---|---|---|---|---|
United Kingdom57 | 220 | 1985 | 1.4% | 3 NHL** |
Sweden and Denmark21 | 176 | 2002 | 2.3% | 4 NHL |
Italy58 | 224 | 2007 | 1.8% | 4 NHL |
ESID+12 | 334 | 2008 | 0.9% | 3 NHL |
Mount Sinai11 | 473 | 2012 | 8.2% | 39 NHL |
ESID+22 | 902 | 2014 | 2.5% | 25 NHL |
Prague23 | 295 | 2018 | 3.7% | 4 NHL; 5 HD; 2 T-cell lymphoma |
ESID+14 | 972 | 2018 | 3.8% | Lymphomas not otherwise specified |
Italy24 | 455 | 2018 | 8.4% | 33 NHL; 5 HD |
USIDNET*20 | 1,285 | 2018 | 2.9% | 37 NHL |
Duke University26 | 198 (91 pediatric-onset; 107 adult-onset) | 2019 | 9.1% | 18 NHL/leukemia |
Note:
ESID: European Society for Immunodeficiencies; HD: Hodgkin lymphoma.
USIDNET: United States Immunodeficiency Network.
NHL: non-Hodgkin lymphoma.